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Abstract
A lipid coated calcium phosphate (LCP) nanoparticle (NP) formulation was developed for efficient
delivery of small interfering RNA (siRNA) to a xenograft tumor model by intravenous
administration. Based on the previous formulation, liposome-polycation-DNA (LPD), which was
DNA-protamine complex wrapped by cationic liposome followed by post-insertion of PEG, LCP
was similar to LPD NP except that the core was replaced by a biodegradable nano-sized calcium-
phosphate precipitate prepared by using water-in-oil micro-emulsions in which siRNA was
entrapped. We hypothesized that after entering the cells, LCP would de-assemble at low pH in the
endosome, which would cause endosome swelling and bursting to release the entrapped siRNA. Such
a mechanism was demonstrated by the increase of intracellular Ca2+ concentration as shown by using
a calcium specific dye Fura-2. The LCP NP was further modified by post-insertion of polyethylene
glycol (PEG) with or without anisamide, a sigma-1 receptor ligand for systemic administration.
Luciferase siRNA was used to evaluate the gene silencing effect in H-460 cells which were stably
transduced with a luciferase gene. The anisamide modified LCP NP silenced about 70% and 50% of
luciferase activity for the tumor cells in culture and those grown in a xenograft model, respectively.
The un-targeted NP showed a very low silencing effect. The new formulation improved the in
vitro silencing effect 3–4 folds compared to the previous LPD formulation, but had a negligible
immunotoxicity.
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1 Introduction
Non-viral vector for the delivery of nucleic acid has been studied since the 1990s. We have
designed a modular method to assemble a core/shell NP structure which was named LPD [1–
4]. The negatively charged DNA-protamine core allows subsequent wrapping by cationic
liposomes. The resulting positively charged NP were further modified by inserting double-
chain phospholipid conjugate of polyethylene glycol (PEG) to impart a steric barrier for
prolonged circulation time in the blood. The distal end of PEG is tethered with a small targeting
ligand such as anisamide for rapid and specific internalization of the bound NP [5]. Although
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LPD showed a striking success in delivering siRNA after intravenous injection, the release of
siRNA into the cytoplasm is variable depending on the cells and still has room for improvement.
Large molecular weight carbohydrate, hyaluronic acid, has been used to replace the DNA in
LPD formulation which caused immunotoxicity [6].
Calcium phosphate (CaP) is a well used non-viral vector for in vitro transfection of a wide
variety of mammalian cells with little toxicity[7]. The delivery activity is probably related to
the fact that CaP rapidly dissolves in the acidic pH [8] Endocytosed CaP is expected to de-
assemble in the endosomes and release its cargo into the cytoplasm. Many investigators,
including ourselves, have attempted to improve the manufacture of the CaP precipitate with
limited success [9]. Many other approaches have been attempted to prepare nano-sized CaP
particles to improve the transfection reproducibility and efficiency. For example, Maitra and
colleagues condensed DNA in a reverse micro-emulsion environment to prepare CaP NPs of
100–120 nm in diameter [8,10,11]. The colloids aggregate rapidly with time and only in
vitro transfection has been reported. Epple et al. developed a formulation of CaP NPs by rapid
precipitation followed by immediate adsorption of DNA or siRNA, which also stabilized the
CaP colloids [12–14]. The stabilized NPs showed 100–200 nm in size and could transfect cells
with a GFP plasmid or silenced the expression of GFP in the treated cells. Liu et al. reported
a preparation of 24–35 nm CaP NPs coated with bovine serum albumin as a DNA vector in
vitro [15]. However, the formulation was not tested via systemic administration. Thus, it would
be a great improvement if one could combine the advantage of LPD and CaP NP to achieve a
prolonged circulation time and an elevated endosome release mechanism.
Thus, we have replaced the core of LPD NP with the acid-sensitive CaP. The resulting new
formulation is called Liposome/Calcium/Phosphate, or LCP. The CaP core should dissolve in
the endosomes, causing osmotic swelling to release the encapsulated siRNA. After further
modification of a targeting ligand with a PEG linker, the LCP NP showed excellent siRNA
delivery activity in cultured tumor cells and in a xenograft tumor model.
2 Materials and Methods
2.1 Materials
1 ,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP), cholesterol, 1,2-
distearoryl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol-2000)
ammonium salt (DSPE-PEG) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL).
DSPE-PEG-anisamide was synthesized in our lab as described elsewhere [16]. Fura-2 AM was
purchased from Invitrogen Inc. (Carlsbad, CA) and dissolved in DMSO to prepare 1 mM store
solution. Anti-luciferase siRNA (target sequence 5'-CTT ACG CTG AGT ACT TCG A-3')
was purchased from Dharmacon (Lafayette, CO) in deprotected, desalted, annealed form. Other
chemicals were obtained from Sigma-Aldrich (St. Louis, MO) without further purification.
NCI-H-460 cells (human lung cancer cells) were obtained from American Type Culture
Collection and were stably transduced with GL3 firefly luciferase gene using a retroviral vector
produced in Dr. Pilar Blancafort’s lab at the University of North Carolina at Chapel Hill. The
cells were maintained in RPMI 1640 cell culture medium with 10% fetal bovine serum
(Invitrogen, Carlsbad, CA), 100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen,
Carlsbad, CA). H460 cells were previously shown to be sigma-1 receptor positive [1].
2.2 Experimental animals
Female athymic nude mice of age 6–8 weeks were purchased from Charles River Laboratories
(Wilmington, MA). All work performed on animals were in accordance with and approved by
the University of North Carolina Institutional Animal Care and Use Committee.
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2.3 The preparation of LCP
Fig. 1 shows a diagram for the preparation of the lipid coated calcium phosphate (LCP) NP.
Briefly, 250 mM CaCl2 and 250 mM NaHPO4 solutions were prepared in aqueous solution
and both of the pH values were adjusted by 1 M ammonium to pH 9. One hundred and fifty µl
of CaCl2 100 µl of NaHPO4 with 25 µl anti-luciferase siRNA (2mg/ml) were dispersed in 7
ml cyclohexane/Triton-X100/hexanol to form a reverse water-in-oil micro-emulsion,
respectively. After mixing the above two solution for 15 min, 125 µl of 15 mM sodium citrate
was added dropwise to the micro-emulsion and the solution continued to be transparent. With
the incubation for another 15 min, 1 g silica gel (60–200 mesh) was added to absorb the formed
calcium phosphate nano-precipitate with the entrapped siRNA. The silica gel was washed by
ethanol and eluting with ethanol/water (3/1, volume ratio). The calcium phosphate core with
siRNA could be stored in elution solution for at least one week.
The obtained NP core was dispersed in water after removing ethanol by rotary evaporation and
mixed with 1:1 molar ratio of DOTAP-cholesterol (10 mM total lipid) liposome extruded by
a 100 nm membrane for more than 15 times to form the unmodified LCP. The amount of
DOTAP was optimized by detecting the Z-potential of LCP in 1 mM KCl by a Zeta Plus
potential analyzer (Brookhaven Instrument Corporation, Holtsville, NY) and the size of the
unmodified LCP was determined by a submicron particle sizer (NICOMP particle sizing
system, AutodilutePAT Model 370, Santa Barbra, CA).
To qualitatively calculate the trapping efficiency of siRNA in LCP nanoparticle, the anti-
luciferase siRNA was replaced by the same sequence siRNA with FAM labeling (Dharmacon
Inc, Lafayette, CO). The FAM-labeled siRNA entrapped LCP nano-particles were dissolved
in the same amount of lysis buffer (2 mM EDTA and 0.05 % Trixton-100 in pH 7.8 Tris buffer)
for quantitative analysis of the siRNA encapsulation efficiency. The standard siRNA solutions
were prepared by diluting the original FAM-labeled siRNA in the same lysis buffer. Then, 100
µl of each standard and LCP solution was taken to the 96-well plate and the fluorescence
intensity was measured on plate reader (Plate Chameleon Multilabel Detection Platform,
Bioscan Inc., Washington DC) to record the fluorescence intensity at 525 nm. The amount of
entrapped siRNA was calculated according to the standard calibration curve.
Transmission electron microscope (TEM) images of the CaP core and resulting LCP were
acquired by the use of JEOL 100CX II TEM (JEOL, Japan). Briefly, 5 µl of CaP NP was
dropped on to a 300 mesh carbon coated copper grid (Ted Pella, Inc., Redding, CA). For LCP,
1% uranyl acetate was used to stain the NP for 5 min before the observation with TEM.
Untargeted LCP and targeted LCP were prepared by incubating 330 µl unmodified LCP (10
mM lipid) with 37.8 µl DSPE-PEG2000 or DSPE-PEG-anisamide (10 mg/ml) at 50°C for 10
min, respectively, and then allowed to stand at room temperature for 10 min before use.
Liposome-protamine-DNA (LPD) NP was prepared as previously described [17].
2.4 Calcium release in live cells by LCP
Two µl of 2 mM Fura-2 AM and 2 µl of 20% Pluronic-127 were mixed for 5 min and freshly
prepared in 1 ml phenol red free DMEM cell culture medium before usage. About 5×104 H-460
cell was incubated in Lab-Tek 8 well Glass Chamber Slide System (Fisher, Pittsburgh, PA)
for 24 h. Two hundred µl of 2 µM Fura-2 AM solution was added to the cell culture chamber
and incubated for 50 min. After washing by PBS twice, the cells were incubated in phenol red
free DMEM cell culture medium and imaged in Nikon TE2000U microscope with OrcaER
Camera. The emission was monitored at 510 nm with the alternate excitation wavelength of
340 nm and 380 nm from a Xenon light source. After adding 50 µl LCP, the fluorescence image
was obtained by setting excitation at 340 nm for green color and 380 nm for red color. The
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ratio of 340 nm/380 nm was proportional to the intracellular free Ca2+ concentration [18]. All
experiments were performed at room temperature.
For the inhibition of endocytosis, 20 mM cytochalasin D was prepared in DMSO solution and
freshly diluted 1,000 times by phenol red free DMEM medium for usage. After incubated with
Fura-2 AM for 60 min and 20 µM cytochalasin D for 5 min, the cells were imaged as described
with the addition of LCP.
2.5 In vitro luciferase gene silencing study
H-460 cells with stable luciferase expression were seeded in 96 well plates. After reaching
60% confluency, the cells were treated with different formulations of LCP containing anti-
luciferase siRNA in the culture medium at 37°C for 24 h. All of the siRNA was FAM labeled
and calibrated according to the method described in Materials and Methods 2.3. Cells were
washed with PBS twice followed by incubation with 100 µl lysis buffer at 4°C for 1 h. Twenty
µl lysate was mixed with 80 µl substrate (Luciferase Assay System, Promega Co., Madison,
WI) and the luminescence intensity was measured by the plate reader (Bioscan Inc.,
Washington DC). The total protein concentration in the lysate was determined by using a
protein assay kit (Micro BCA™ Protein Assay Kit, Pierce). The activity of luciferase is shown
as the luminescence intensity per µg protein.
Data are presented as the mean ± SD. The statistical significance was determined by using the
analysis of two-sided student t-test. P values of <0.05 were considered to be significant.
2.6 In vivo luciferase gene silencing study
H-460 cells (2×105) with luciferase expression were subcutaneously injected into the lower
back of female nude mice (about 20 g), and allowed to grow to tumor size of about 400
mm3. The mice were randomly assigned to different treatment groups (n=3 for each group).
Mice were tail-vein injected with LCP-PEG or LCP-PEG-AA containing 24 µg anti-luciferase
siRNA or the controlled siRNA, which sequence is 5'-AAT TCT CCG AAC GTG TCA
CGT-3' [17]. Similar LPD formulations containing the identical amounts of anti-luciferase or
control siRNA were also prepared and used for comparison. After 24 h, the tumors were
harvested, weighted and homogenized in lysis buffer with a volume of lysis buffer (ml)/ tumor
weight (g) ratio of 2. The following steps were the same as the in vitro study.
2.7 Immunotoxicity Assay
C57BL/6 mice were i.v. injected with targeted LCP and LPD nanoparticle with the entrapped
anti-luciferase siRNA at 0.6 mg/kg and 1.2 mg/kg. After 4 h of the injection, blood samples
were collected from the tail artery and allowed to stand at room temperature for 0.5 h for
coagulation. Serum was obtained by centrifuging the clotted blood at 13,000 rpm for 20 min.
Cytokine levels were determined by using ELISA kits for IL6 and IL12 (BD Biosciences, San
Diego, CA)
3 Results and Discussion
3.1 The hypothesis of siRNA release from LCP NP in the endosome
One of the key steps in the NP-mediated intracellular delivery of macromolecules, including
siRNA is the release of the cargo from the endosomes. This subject has been recently reviewed
by us [19]. Several mechanisms have been explored to explain how DNA/polymer complex,
i.e., polyplex, could escape from the endosome. The well accepted proton sponge effect [20]
is probably not the major mechanism of endosome escape of the polyplex, because free cationic
polymer is required for activity [21]. Ion-pair formation between the cationic groups of the
polymer and anionic lipids in the endosome membrane is more likely the mechanism [22].
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However, it is also necessary to coat the NP with a PEG layer to prolong the circulation time
and enhance the tumor uptake via the enhanced permeability and retention (EPR) effect [23].
PEG layer on the surface of the NP effectively shields the positive charges such that no
significant ion pairs can be formed with the endosome lipids. This is probably why much of
the internalized siRNA in the LPD NP is still sequestered in the endosomes [2]. Thus, the
release mechanism for nucleic acid from the PEGylated NP into the cytoplasm could still be
significantly improved.
As the oldest non-viral gene vector, calcium phosphate (CaP) composites could encapsulate
nucleic acid due to the high affinity of Ca ion to the phosphate groups in the nucleic acids
[24,25]. After being taken up by the cell, the composite is dissolved in the acidic environment
of the endosome and releases the encapsulated nucleic acid into the cytoplasm. Therefore, the
release of nucleic acid is not related to the ion-pair formation and has the potential to improve
the release of nucleic acid from PEGylated NP from the endosome. The hypothesis of the
release is shown in Figure 2.
As shown in the Figure 2, there are several steps for siRNA released from LCP. (1) The LCP
enters the cell through the endocytosis and stays in the endosome. (2) The CaP core is dissolved
at low pH, causing NP de-assembly. (3) The dissolved calcium and phosphate ions increase
the osmotic pressure and cause endosome swelling. (4) The endosome bursts and release the
siRNA, calcium and phosphate ions into the cytoplasm.
Since we do not change the shell of the NP, PEGylated and ligand targeted LCP is expected
to accumulate in the tumor by the EPR effect, just like LPD [17].
3.2 The characteristics of LCP NP
To encapsulate siRNA in nano-scale particles, the nucleic acid should be confined in a nano-
sized space when the particles are assembled. We have used a reverse water-in-oil micro-
emulsion to entrap siRNA by calcium phosphate precipitate in a nano-sized reactor.
Furthermore, the particles should contain a negatively charged surface for coating with
positively charged liposome[26]. This was done by adding 125 µl of 15 mM sodium citrate to
the micro-emulsion [27]. The organic solvent and surfactant were removed by immobilizing
the CaP NP in silica gel and extensively washed by EtOH and water. The resulting spherically
shaped CaP NP (Figure 3A) was fairly homogenous with an average diameter of about 60–80
nm. Addition of EtOH or acetone to the micro-emulsion followed by centrifugation was also
attempted to separate the NP from the surfactants. Large sized precipitate was always obtained
due to the aggregate of the NP (data not shown). The addition of citrate also played a critical
role to stabilize the formed CaP NP because citrate was absorbed on the surface of NP to have
a negative charge. In this process, 15 mM citrate was chosen to endow the CaP NP with a zeta
potential about −14 to −20 mV. Thus, the resulting CaP NP could serve as the cores for the
formation of LCP.
The particle size and zeta potential of the LCP depended on the ratio of DOTAP/cholesterol
liposome to CaP NP. As shown in Figure 3C, the CaP NP in this representative experiment
was about 80nm in size with a zeta potential about −16 mV. The addition of DOTAP/cholesterol
liposome caused an increase in the zeta potential of the complex until a neutrally charged yet
very large aggregate (900 nm) formed at the ratio of 417 since the net charge of positive charged
liposome and negative charged calcium phosphate core are equal. With the continuous addition
of DOTAP/cholesterol liposome, the complex showing a positive charge and stable colloids
with a size of approximately 150 nm were obtained. The surface charge continuously increased
to +38 mV with a stable size of 150 nm until the ratio reached 834. To assure the CaP NP was
fully covered by the liposome, a slight excess lipid was used at the ratio of 973 and the final
particles showed a zeta potential of about +40 mV and an average diameter of 150 nm. With
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the negative staining, the TEM imaging showed a coated layer on the calcium phosphate core
(Figure 3B), i.e. LCP NP was obtained. Using a fluorescence labeled siRNA, the final
encapsulation efficiency of siRNA in LCP was measured to be 39.8±2.8% (n=3).
It is difficult to avoid empty liposomes if excess liposomes were added to the calcium phosphate
cores. However, the amount of cationic liposomes has been carefully titrated such that the total
positive charge in added cationic liposomes was roughly the same as the total negative charges
on the cores. Under such condition, there should be no excess empty liposomes in the final
preparation.
3.3 Imaging of intracellular calcium release from LCP NP
It is well known that the CaP precipitate rapidly dissolves at an acidic pH and releases calcium
ions. Protons should be able to penetrate the lipid membrane of LCP to dissolve the CaP core.
The colloid CaP and LCP showed a light scattering absorbance at 275nm and 270 nm,
respectively. We have tested the dynamic change of light scattering at different pH as shown
in Figure 4A. At neutral pH 7.0, both CaP and LCP remained unchanged during the period of
time tested, i.e., 10 min. When the pH was dropped to 6.0, 30% of the CaP NP disappeared
after 10 min, but the LCP NP did not change too much. With continuous drop of pH, the light
scattering of LCP NP decreased 60% in 10 min, showing a significant acid-sensitive
characteristic. It is well known that the pH value in the endosome of tumor cells can be as low
as 5.0. Thus, the LCP NP should de-assemble at this pH and release its cargo, i.e., siRNA. This
observation was in accordance with the hypothesis shown in Figure 2.
Fura-2-acetoxymethyl ester (Fura-2 AM), is a membrane permeable derivative of Fura-2 to
measure cellular calcium concentrations by fluorescence imaging. After entering the cell
membrane, Fura-2 AM is converted to Fura-2 by cellular esterase. Fura-2 binds with
intracellular free calcium and blue-shifts its emission [18]. The ratio of the emissions at 340
nm and 380 nm is directly correlated to the amount of intracellular calcium [28]. After loading
with 2 µM Fura-2 AM, the tumor cells were incubated with the unmodified LCP and imaged
by confocal microscopy as shown in Figure 4B. A significant color change was observed in
the cells after the addition of LCP. White arrows indicate representative cells changing color
from orange/red (low calcium) to green (high calcium) although not all of the cells changed
their color. Since unmodified LCP is positively charged, we checked to see if the color change
of cells was the result of interacting with cationic particles. DOTAP/cholesterol liposome (+40
mV in zeta potential) was added to Fura-2 labeled cells. The liposome did not cause any color
change, thus ruling out the possibility (data not shown). To verify that the color change really
came from the release of calcium in LCP, an endocytosis inhibitor, cytochalasin D, was used
to inhibit the endocytosis of LCP in the tumor cells. The addition of cytochalasin D significantly
reduced the change of color from orange/red to green, showing the uptake of LCP NP was
endocytosis dependent (data not shown). These results strongly support the hypothesis
described in Figure 2.
3.4 In vitro luciferase gene silencing effect of LCP
The in vitro silencing study was performed by using H-460 cells stably expressing firefly
luciferase. Figure 5A showed the silence effect of anti luciferase siRNA in different
formulations. Free siRNA does not have any silence effect because free siRNA can not
penetrate the lipid membrane of cells. The naked or unmodified LCP NP showed a large silence
effect but it also showed toxicity due to its cationic charges. PEGylated, but untargeted, LCP
(LCP-PEG) showed a 20% silencing effect, probably because the positive charge on LCP was
sheltered to reduce the endocytosis. Compared to the untargeted PEGylated LPD formulation
(LPD-PEG), the slight enhancement in silencing may be caused by the solid core of calcium
phosphate. The AA targeted LCP (LCP-PEG-AA) had a significantly improved silencing effect
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compared to PEGylated but untargeted LCP (LCP-PEG) and down-regulated more than 60%
of the luciferase expression when the concentration of siRNA equaled to 100 nM (n=3).
However, the targeted LPD (LPD-PEG-AA) only silenced 20% of the luciferase expression at
the same concentration of the siRNA. If the control siRNA was entrapped in calcium phosphate
and prepared as the LCP-PEG and LCP-PEG-AA formulations, there was no silence effect
observed. The fact that LCP formulations always showed a stronger silencing effect than the
corresponding LPD formulations can be seen in Figure 5B. The IC50, half maximal inhibitory
concentration, of LCP was calculated to be 60 nM, which is three to four times lower than that
of LPD (200 nM).
The cytotoxicity for LCP formulations were measured by MTT assay, which include the
untreated group, luciferase siRNA in non-target LCP, luciferase siRNA in target LCP, control
siRNA in target LCP and luciferase siRNA in the LPD formulation. The results were
summarized as a supplemental figure 1. Similar to our previous formulation LPD, the in
vitro experiments showed that there was no cytotoxicity for LCP with PEG coating or with
PEG-AA coating. Compared to the untreated group, the survival values in all of these groups
were from 98% to 103%. There were no significant difference between the groups because the
protection of PEG on the outer layer.
3.5 In vivo luciferase gene silencing effect of LCP
The in vivo luciferase gene silencing effect was demonstrated on a xenograft model by
implanting H-460 cells to the nude mice. As shown in Figure 6, the PEGylated but untargeted
LCP (LCP-PEG) showed a slight silencing effect to the expression of luciferase. However, the
targeted LCP (LCP-PEG-AA) showed 50% down-regulation effect, which was also similar to
the corresponding LPD formulation. If the anti-luciferase siRNA was replaced by controlled
siRNA, almost no silencing effect was observed in any formulation. This result demonstrated
the siRNA delivery activity of LCP formulation in vivo.
The immunotoxicity study of the targeted LCP and LPD formulations was shown in figure 6
B as the result of C57BL/6 mice. The concentration of two important proinflammatory
cytokines, IL6 and IL 12, in the serum was detected according to our previous study [6, 17].
It was shown that targeted LCP nanoparticle almost did not induce the production of IL 6 when
the siRNA dose was up to 1.2 mg/kg. For the IL 12, there was no increase at the dose of 0.6
mg/kg with a slight increase at the dose of 1.2 mg/kg. However, the LPD formulation caused
a change at the dose of 0.6 mg/kg with a significant increase at the dose of 1.2 mg/kg. Therefore,
the LCP nanoparticle suggested a new approach to increase the delivery dose for in vivo siRNA
therapy.
4. Summary and Conclusion
We have developed a novel LCP nanoparticle formulation with a new cargo release mechanism
that is different from the well established proton sponge effect. The calcium phosphate in the
core of LCP nanoparticles dissolved at low pH in the endosome, increased the osmotic pressure
and caused endosome swelling and bursting to release the entrapped siRNA. The targeted LCP
with a PEG coating showed an improvement gene silence effect in vitro. Compared to the LPD
nanoparticles, the replacement of DNA/protamine complex by calcium phosphate also
decreased the immunotoxicity to promise a potential application for clinical trial.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Li et al. Page 7














The authors would like to thank Dr. Surendar Reddy Bathula for synthesizing the DSPE-PEG-anisamide. We thank
the Michael Hooker Microscopy Facility at UNC for the microscopy images. The project was supported by National
Cancer Institute (CA129835).
References
1. Chen Y, Sen J, Bathula SR, Yang Q, Fittipaldi R, Huang L. Novel Cationic Lipid That Delivers siRNA
and Enhances Therapeutic Effect in Lung Cancer Cells. Mol Pharm. 2009
2. Li SD, Chen YC, Hackett MJ, Huang L. Tumor-targeted delivery of siRNA by self-assembled
nanoparticles. Mol Ther 2008;16(1):163–169. [PubMed: 17923843]
3. Li SD, Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA
into lung cancer cells. Mol Pharm 2006;3(5):579–588. [PubMed: 17009857]
4. Li S, Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA
(LPD) complexes. Gene Ther 1997;4(9):891–900. [PubMed: 9349425]
5. Mukherjee A, Prasad TK, Rao NM, Banerjee R. Haloperidol-associated stealth liposomes: a potent
carrier for delivering genes to human breast cancer cells. J Biol Chem 2005;280(16):15619–15627.
[PubMed: 15695518]
6. Chono S, Li SD, Conwell CC, Huang L. An efficient and low immunostimulatory nanoparticle
formulation for systemic siRNA delivery to the tumor. J Control Release 2008;131(1):64–69.
[PubMed: 18674578]
7. Sokolova V, Epple M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew Chem Int
Ed Engl 2008;47(8):1382–1395. [PubMed: 18098258]
8. Bisht S, Bhakta G, Mitra S, Maitra A. pDNA loaded calcium phosphate nanoparticles: highly efficient
non-viral vector for gene delivery. Int J Pharm 2005;288(1):157–168. [PubMed: 15607268]
9. Olton D, Li J, Wilson ME, Rogers T, Close J, Huang L, Kumta PN, Sfeir C. Nanostructured calcium
phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on
transfection efficiency. Biomaterials 2007;28(6):1267–1279. [PubMed: 17123600]
10. Maitra A. Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy.
Expert Rev Mol Diagn 2005;5(6):893–905. [PubMed: 16255631]
11. Roy I, Mitra S, Maitra A, Mozumdar S. Calcium phosphate nanoparticles as novel non-viral vectors
for targeted gene delivery. Int J Pharm 2003;250(1):25–33. [PubMed: 12480270]
12. Eufinger H, Rasche C, Lehmbrock J, Wehmoller M, Weihe S, Schmitz I, Schiller C, Epple M.
Performance of functionally graded implants of polylactides and calcium phosphate/calcium
carbonate in an ovine model for computer assisted craniectomy and cranioplasty. Biomaterials
2007;28(3):475–485. [PubMed: 16996127]
13. Sokolova VV, Radtke I, Heumann R, Epple M. Effective transfection of cells with multi-shell calcium
phosphate-DNA nanoparticles. Biomaterials 2006;27(16):3147–3153. [PubMed: 16469375]
14. Welzel T, Meyer-Zaika W, Epple M. Continuous preparation of functionalised calcium phosphate
nanoparticles with adjustable crystallinity. Chem Commun (Camb) 2004;(10):1204–1205. [PubMed:
15136839]
15. Liu T, Tang A, Zhang G, Chen Y, Zhang J, Peng S, Cai Z. Calcium phosphate nanoparticles as a
novel nonviral vector for efficient transfection of DNA in cancer gene therapy. Cancer Biother
Radiopharm 2005;20(2):141–149. [PubMed: 15869447]
16. Banerjee R, Tyagi P, Li S, Huang L. Anisamide-targeted stealth liposomes: a potent carrier for
targeting doxorubicin to human prostate cancer cells. Int J Cancer 2004;112(4):693–700. [PubMed:
15382053]
17. Li SD, Chono S, Huang L. Efficient gene silencing in metastatic tumor by siRNA formulated in
surface-modified nanoparticles. J Control Release 2008;126(1):77–84. [PubMed: 18083264]
18. Hirst RA, Harrison C, Hirota K, Lambert DG. Measurement of [Ca2+]i in whole cell suspensions
using fura-2. Methods Mol Biol 1999;114:31–39. [PubMed: 10081008]
19. Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev.
2009
Li et al. Page 8













20. Thomas M, Klibanov AM. Enhancing polyethylenimine's delivery of plasmid DNA into mammalian
cells. Proc Natl Acad Sci U S A 2002;99(23):14640–14645. [PubMed: 12403826]
21. Yang S, May S. Release of cationic polymer-DNA complexes from the endosome: A theoretical
investigation of the proton sponge hypothesis. J Chem Phys 2008;129(18):185105. [PubMed:
19045433]
22. Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular
delivery of polynucleic acids. Gene Ther 2001;8(15):1188–1196. [PubMed: 11509950]
23. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov
2005;4(2):145–160. [PubMed: 15688077]
24. Epple, MaS; V. Inorganic Nanoparticles as Carriers of Nucleic Acids into Cells. Angewandte Chemie
International Edition 2008;47
25. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA.
Virology 1973;52(2):456–467. [PubMed: 4705382]
26. Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer.
Biochim Biophys Acta. 2009
27. Morgan TT, Muddana HS, Altinoglu EI, Rouse SM, Tabakovic A, Tabouillot T, Russin TJ,
Shanmugavelandy SS, Butler PJ, Eklund PC, Yun JK, Kester M, Adair JH. Encapsulation of organic
molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery.
Nano Lett 2008;8(12):4108–4115. [PubMed: 19367837]
28. Wier WG, Beuckelmann DJ, Barcenas-Ruiz L. [Ca2+]i in single isolated cardiac cells: a review of
recent results obtained with digital imaging microscopy and fura-2. Can J Physiol Pharmacol 1988;66
(9):1224–1231. [PubMed: 3064899]
Li et al. Page 9














The formation process of liposome/calcium/phosphate (LCP) nanoparticles.
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The hypothesized release process of siRNA entrapped in LCP after endocytosis to the
endosome. There are four steps for siRNA released from LCP. (1) The LCP enters the cell
through endocytosis and stays in the endosome. (2) The CaP core is dissolved at low pH,
causing NP de-assembly. (3) The dissolved calcium and phosphate ions increase the osmotic
pressure and cause endosome swelling. (4) The endosome bursts and releases the siRNA,
calcium and phosphate ions into the cytoplasm.
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The TEM imaging of (A) siRNA entrapped in calcium phosphate. (B) The LCP nanoparticle
with negative staining. (C) Effect of lipid/siRNA molar ratio on particle size and zeta potential
of LCP.
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The release profile of LCP. Light scattering of CaP/siRNA (A) and siRNA in LCP (B) at
different pH. The fluorescence images of Fura-2 labeled H-460 cells before (C) and after (D)
the addition of LCP. The arrows indicate cells that changed color from red (low Ca2+) to green
(high Ca2+).
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(A) In vitro luciferase gene silencing effect of different formulations in H-460 cells by
incubation at 37°C for 24 h (n=5). The amount of siRNA in LCP formulation was 99.8±6.9
nM by evaluating the entrapped fluorescently labeled siRNA. For the LPD formulations, the
concentration of FAM labeled siRNA was 100 nM. (B) The measurement of IC50, half
maximal inhibitory concentration, of LCP-PEG-AA and LPD-PEG-AA. * indicates p<0.05,
** indicates p<0.01.
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(A) In vivo luciferase gene silencing effects of different formulations at the dose of 1.2 mg/
kg. The luciferase activity in H-460 cells was measured after 24 hours of the i.v. injection with
different siRNA formulations. (B) The serum IL-6 (solid line) and IL-12 (dash line) levels of
the mice after 4 hours of the i.v. injection with targeted LCP (squares) and LPD (circles)
formulations at different dose of siRNA. ** indicates p<0.01.
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